Structural modifications induced by specific HIV-1 protease-compensatory mutations have an impact on the virological response to a first-line lopinavir/ritonavir-containing regimen

Claudia Alteri, Anna Artese, Gertjan Beheydt, Maria Mercedes Santoro, Giosué Costa, Lucia Parrotta, Ada Bertoli, Caterina Gori, Nicoletta Orchi, Enrico Girardi, Andrea Antinori, Stefano Alcaro, Antonella D Arminio Monforte, Kristof Theys, Anne Mieke Vandamme, Francesca Ceccherini-Silberstein, Valentina Svicher, Carlo Federico Perno

Research output: Contribution to journalArticlepeer-review

Abstract

Objectives: This study evaluates the impact of specific HIV-1 protease-compensatory mutations (wild-type amino acids in non-B subtypes) on virological response to a first-line lopinavir/ritonavir-containing regimen in an HIV-1 subtype B-infected population. Patients and methods: The prevalence of protease-compensatory mutations from1997 to 2011was calculated in 3063 drug-naive HIV-1 B-infected patients. The role of these mutations on virological outcome is estimated in a subgroup of 201 patients starting their first lopinavir/ritonavir-containing regimen by covariation and docking analyses. The number of HIV-1 B-infected patients with at least one protease-compensatory mutation increased over time (from86.4% prior to 2001 to 92.6% after 2009, P1/40.02). Analysing 201 patients starting first-line lopinavir/ritonavir, the median time to virological failure was shorter in patients with at least one protease-compensatory mutation than in patients with no protease-compensatory mutations. By covariation and docking analyses, specific mutations were found to affect lopinavir affinity for HIV-1 protease and to impact virological failure. Specifically, the L10V+I13V+L63P+I93L cluster, related to fast virological failure, correlated with a decreased drug affinity for the enzyme in comparison with wild-type (ΔGmut=-30.0 kcal/mol versus ΔGwt=-42.3 kcal/mol). Our study shows an increased prevalence of specific protease-compensatory mutations in an HIV-1 B-infected population and confirms that their copresence can affect the virological outcome in patients starting a lopinavir/ritonavir-containing regimen.

Original languageEnglish
Article numberdkt173
Pages (from-to)2203-2209
Number of pages7
JournalJournal of Antimicrobial Chemotherapy
Volume68
Issue number10
DOIs
Publication statusPublished - Oct 2013

Keywords

  • Antiviral
  • Drug resistance
  • Molecular modelling

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)
  • Infectious Diseases
  • Medicine(all)

Fingerprint Dive into the research topics of 'Structural modifications induced by specific HIV-1 protease-compensatory mutations have an impact on the virological response to a first-line lopinavir/ritonavir-containing regimen'. Together they form a unique fingerprint.

Cite this